Abstract

The final assessment report and related documents concerning OTCA18, ‘regional hyperthermia for high-risk soft tissue sarcoma treatment’, are now available.

The assessed technology is regional hyperthermia added to conventional therapies to treat high-risk soft tissue sarcoma. The objective of this rapid relative effectiveness assessment was to collaboratively address the research question: Is the regional application of non-invasive external hyperthermia administered in addition to chemo- and/or radiotherapy more effective and/or safer for oncological patients with high-risk soft tissue sarcoma than radio- and/or chemotherapy alone?